

## Survey for antibodies against Epstein-Barr virus

EQA Provider: ESfEQA GmbH  
Heidelberg

ESfEQA Head of Operations: Dr. D. Groche

### Instructions for Use

#### Notes:

The samples should be considered as potentially infectious. The usual precautions in the laboratory for potentially hazardous material apply for these samples. The blood donations used for production were found to be non-reactive for HBsAg, anti-HIV 1/2 and anti-HCV. The samples should be handled by trained personnel only.



**WARNING:** Contains methylisothiazolones. H317 May cause allergic skin reaction.



This product contains human source material and should be considered as potentially infectious.

Various tasks of the proficiency testing scheme may occasionally be given over to qualified subcontractors. However, ESfEQA is responsible to the participants for the subcontractor's work.

Results from sample analysis may only be disclosed to colleagues from other laboratories after the testing period has been concluded.

By registering for and participating in this EQA participants agree to accept the general terms and conditions of ESfEQA GmbH. These can be retrieved online at [www.esfeqa.eu](http://www.esfeqa.eu).

#### 1. Intended Use

The samples are intended for use as qualitative control material for External Quality Assessment (EQA) in medical laboratories for antibodies against Epstein-Barr virus:

anti-EBV VCA IgG + total  
anti-EBV EBNA IgG + total  
anti-EBV VCA IgM

#### 2. Product Description

Sample 1: EBV\_2023\_01\_a  
Sample 2: EBV\_2023\_01\_b  
Sample 3: EBV\_2023\_02\_a  
Sample 4: EBV\_2023\_02\_b

The samples are liquid, ready-to-use.

#### 3. Storage and Stability

The samples should be stored upright at 2-8 °C. They are stable at least until the deadline for data submission as indicated below.

#### 4. Sample Preparation and Analysis

Allow the sample to equilibrate to room temperature for a minimum of 15 minutes prior to testing. Directly before use, gently agitate the sample by inverting the vial several times.

All samples should be treated the same way as patient samples and run in accordance with the instructions of the instrument and reagent manufacturer.

#### 5. Dates and Submission of Test Results

Testing Period for Sample 1 and 2: 13/02/23 - 06/03/23

Testing Period for Sample 3 and 4: 10/04/23 - 02/05/23

Please submit your results electronically to ESfEQA at <https://teqa.esfeqa.eu>.

Contact your local distributor of ESfEQA programs or ESfEQA directly if you need assistance with registration in TEQA. Alternatively, though not preferred, use the fax form provided on the ESfEQA website. In both cases indicate the instrument and method used for the analysis of the samples.

#### 6. Deadline for Data Submission

Deadline for data submission (time zone GMT +1):

Sample 1 and 2:	06/03/23
Sample 3 and 4:	02/05/23

#### 7. Reports and Certificates

The data will be evaluated by ESfEQA. The individual laboratory reports and certificates can be retrieved online at <https://teqa.esfeqa.eu>. The reports and certificates will be available within 3 weeks after the deadline of data submission.